Literature DB >> 22554719

Fibroblast growth factor 23 and Inflammation in CKD.

Jair Munoz Mendoza1, Tamara Isakova, Ana C Ricardo, Huiliang Xie, Sankar D Navaneethan, Amanda H Anderson, Lydia A Bazzano, Dawei Xie, Matthias Kretzler, Lisa Nessel, L Lee Hamm, Lavinia Negrea, Mary B Leonard, Dominic Raj, Myles Wolf.   

Abstract

BACKGROUND AND OBJECTIVES: Levels of fibroblast growth factor 23 (FGF23) and inflammatory markers are commonly elevated in CKD, and each is associated with adverse clinical outcomes. This study tested the hypothesis that FGF23 is independently associated with inflammation in CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The association between levels of FGF23 and the inflammatory markers IL-6, C-reactive protein (CRP), TNF-α, and fibrinogen was assessed in a cross-sectional analysis of 3879 participants enrolled in the Chronic Renal Insufficiency Cohort (CRIC) study between June 2003 and September 2008.
RESULTS: FGF23 correlated directly with IL-6 (r=0.4), CRP (r=0.2), TNF-α (r=0.4), and fibrinogen (r=0.3; P<0.001 for each). In univariate and multivariable-adjusted linear regression analyses, natural log (ln) transformed FGF23 was significantly associated with lnIL-6, lnCRP, lnTNF-α, and fibrinogen (P<0.001 for each). Each unit higher lnFGF23 was associated with severe inflammation, defined as levels of all inflammatory markers in the highest 25th percentile, in univariate (odds ratio [OR], 2.4 [95% confidence interval (CI), 2.0-2.9]) and multivariable-adjusted (OR, 2.0 [95% CI, 1.6-2.5]) logistic regression analyses. Ascending FGF23 quartiles were independently associated with severe inflammation (OR, 5.6 for the highest versus lowest FGF23 quartile [95% CI, 2.3-13.9]; P for trend < 0.001).
CONCLUSIONS: Higher FGF23 levels are independently associated with higher levels of inflammatory markers in patients with CKD and with significantly greater odds of severe inflammation. Future studies should evaluate whether inflammation modifies the association between FGF23 and adverse outcomes in CKD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22554719      PMCID: PMC3386678          DOI: 10.2215/CJN.13281211

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  46 in total

1.  Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21.

Authors:  Hiroshi Kurosu; Mihwa Choi; Yasushi Ogawa; Addie S Dickson; Regina Goetz; Anna V Eliseenkova; Moosa Mohammadi; Kevin P Rosenblatt; Steven A Kliewer; Makoto Kuro-o
Journal:  J Biol Chem       Date:  2007-07-10       Impact factor: 5.157

Review 2.  Endocrine functions of bone in mineral metabolism regulation.

Authors:  L Darryl Quarles
Journal:  J Clin Invest       Date:  2008-12-01       Impact factor: 14.808

3.  Severely reduced production of klotho in human chronic renal failure kidney.

Authors:  N Koh; T Fujimori; S Nishiguchi; A Tamori; S Shiomi; T Nakatani; K Sugimura; T Kishimoto; S Kinoshita; T Kuroki; Y Nabeshima
Journal:  Biochem Biophys Res Commun       Date:  2001-02-02       Impact factor: 3.575

4.  Inflammation and cardiovascular risk in dialysis patients.

Authors:  Christoph Wanner; Josef Zimmermann; Susanne Schwedler; Thomas Metzger
Journal:  Kidney Int Suppl       Date:  2002-05       Impact factor: 10.545

5.  TNFalpha and PTH utilize distinct mechanisms to induce IL-6 and RANKL expression with markedly different kinetics.

Authors:  Jia C Dai; Ping He; Xin Chen; Edward M Greenfield
Journal:  Bone       Date:  2005-11-28       Impact factor: 4.398

6.  A high calcium-phosphate product is associated with high C-reactive protein concentrations in hemodialysis patients.

Authors:  Ezio Movilli; Annalisa Feliciani; Corrado Camerini; Giulio Brunori; Roberto Zubani; Francesco Scolari; Giovanni Parrinello; Giovanni C Cancarini
Journal:  Nephron Clin Pract       Date:  2005-08-09

7.  Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences.

Authors:  Guillaume Jean; Eric Bresson; Jean-Claude Terrat; Thierry Vanel; Jean-Marc Hurot; Christie Lorriaux; Brice Mayor; Charles Chazot
Journal:  Nephrol Dial Transplant       Date:  2008-10-13       Impact factor: 5.992

8.  Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.

Authors:  Orlando M Gutiérrez; Michael Mannstadt; Tamara Isakova; Jose Alejandro Rauh-Hain; Hector Tamez; Anand Shah; Kelsey Smith; Hang Lee; Ravi Thadhani; Harald Jüppner; Myles Wolf
Journal:  N Engl J Med       Date:  2008-08-07       Impact factor: 91.245

Review 9.  Classification of obesity and assessment of obesity-related health risks.

Authors:  Louis J Aronne
Journal:  Obes Res       Date:  2002-12

10.  Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial.

Authors:  Pooneh Alborzi; Nina A Patel; Carla Peterson; Jennifer E Bills; Dagim M Bekele; Zerihun Bunaye; Robert P Light; Rajiv Agarwal
Journal:  Hypertension       Date:  2008-07-07       Impact factor: 10.190

View more
  108 in total

Review 1.  Biology of Fibroblast Growth Factor 23: From Physiology to Pathology.

Authors:  Marie Courbebaisse; Beate Lanske
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

2.  The Authors Reply.

Authors:  Katherine Wesseling-Perry
Journal:  Kidney Int       Date:  2015-09       Impact factor: 10.612

3.  Markers of vitamin D metabolism and incidence of clinically diagnosed abdominal aortic aneurysm: The Atherosclerosis Risk in Communities Study.

Authors:  Pamela L Lutsey; Mary R Rooney; Aaron R Folsom; Erin D Michos; Alvaro Alonso; Weihong Tang
Journal:  Vasc Med       Date:  2018-02-05       Impact factor: 3.239

4.  FGF23 protein expression in coronary arteries is associated with impaired kidney function.

Authors:  Natalie A van Venrooij; Renata C Pereira; Yin Tintut; Michael C Fishbein; Navdeep Tumber; Linda L Demer; Isidro B Salusky; Katherine Wesseling-Perry
Journal:  Nephrol Dial Transplant       Date:  2014-01-23       Impact factor: 5.992

5.  Serum fibroblast growth factor-23 and incident hypertension: the Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Amber L Fyfe-Johnson; Alvaro Alonso; Elizabeth Selvin; Julie K Bower; James S Pankow; Sunil K Agarwal; Pamela L Lutsey
Journal:  J Hypertens       Date:  2016-07       Impact factor: 4.844

Review 6.  Haemodialysis-induced hypoglycaemia and glycaemic disarrays.

Authors:  Masanori Abe; Kamyar Kalantar-Zadeh
Journal:  Nat Rev Nephrol       Date:  2015-04-07       Impact factor: 28.314

Review 7.  The systemic nature of CKD.

Authors:  Carmine Zoccali; Raymond Vanholder; Ziad A Massy; Alberto Ortiz; Pantelis Sarafidis; Friedo W Dekker; Danilo Fliser; Denis Fouque; Gunnar H Heine; Kitty J Jager; Mehmet Kanbay; Francesca Mallamaci; Gianfranco Parati; Patrick Rossignol; Andrzej Wiecek; Gerard London
Journal:  Nat Rev Nephrol       Date:  2017-04-24       Impact factor: 28.314

Review 8.  Non-renal-Related Mechanisms of FGF23 Pathophysiology.

Authors:  Mark R Hanudel; Marciana Laster; Isidro B Salusky
Journal:  Curr Osteoporos Rep       Date:  2018-12       Impact factor: 5.096

Review 9.  Fibroblast growth factor 23 and α-Klotho co-dependent and independent functions.

Authors:  L Darryl Quarles
Journal:  Curr Opin Nephrol Hypertens       Date:  2019-01       Impact factor: 2.894

Review 10.  Inflammation regulates fibroblast growth factor 23 production.

Authors:  Connor Francis; Valentin David
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-07       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.